Noone AM, Howlader N, Krapcho M, et al. SEER cancer statistics review (CSR), 1975–2015. Accessed April 1, 2023. Available at: https://seer.cancer.gov/archive/csr/1975_2015/

• PubMed
Noone AM, Howlader N, Krapcho M, SEER cancer statistics review (CSR), 1975–2015. Accessed April 1, 2023. Available at: https://seer.cancer.gov/archive/csr/1975_2015/)| false
• Search Google Scholar
• Export Citation

American Cancer Association. Special section: rare cancers in adults. Accessed April 1, 2023. Available at: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2017/cancer-facts-and-figures-2017-special-section-rare-cancers-in-adults.pdf

• PubMed
American Cancer Association. Special section: rare cancers in adults. Accessed April 1, 2023. Available at: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2017/cancer-facts-and-figures-2017-special-section-rare-cancers-in-adults.pdf)| false
• Search Google Scholar
• Export Citation

Price B, Ware A. Time trend of mesothelioma incidence in the United States and projection of future cases: an update based on SEER data for 1973 through 2005. Crit Rev Toxicol 2009;39:576–588.

• PubMed
Price B, Ware A. Time trend of mesothelioma incidence in the United States and projection of future cases: an update based on SEER data for 1973 through 2005. Crit Rev Toxicol 2009;39:576–588.)| false
• Search Google Scholar
• Export Citation

Tsao AS, Wistuba I, Roth JA, et al. Malignant pleural mesothelioma. J Clin Oncol 2009;27:2081–2090.

• PubMed
Tsao AS, Wistuba I, Roth JA, Malignant pleural mesothelioma. J Clin Oncol 2009;27:2081–2090.)| false
• Search Google Scholar
• Export Citation

National Cancer Institute. Interactive tools, maps, & graphs: SEER* Explorer. Accessed April 1, 2023. Available at: https://seer.cancer.gov/statistics/interactive.html

• PubMed
National Cancer Institute. Interactive tools, maps, & graphs: SEER* Explorer. Accessed April 1, 2023. Available at: https://seer.cancer.gov/statistics/interactive.html)| false
• Search Google Scholar
• Export Citation

Grogg JB, Fronzaroli JN, Oliveira P, et al. Clinicopathological characteristics and outcomes in men with mesothelioma of the tunica vaginalis testis: analysis of published case-series data. J Cancer Res Clin Oncol 2021;147:2671–2679.

• PubMed
Grogg JB, Fronzaroli JN, Oliveira P, Clinicopathological characteristics and outcomes in men with mesothelioma of the tunica vaginalis testis: analysis of published case-series data. J Cancer Res Clin Oncol 2021;147:2671–2679.)| false
• Search Google Scholar
• Export Citation

Carteni G, Manegold C, Garcia GM, et al. Malignant peritoneal mesothelioma—results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent. Lung Cancer 2009;64:211–218.

• PubMed
Carteni G, Manegold C, Garcia GM, Malignant peritoneal mesothelioma—results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent. Lung Cancer 2009;64:211–218.)| false
• Search Google Scholar
• Export Citation

Mirarabshahii P, Pillai K, Chua TC, et al. Diffuse malignant peritoneal mesothelioma—an update on treatment. Cancer Treat Rev 2012;38:605–612.

• PubMed
Mirarabshahii P, Pillai K, Chua TC, Diffuse malignant peritoneal mesothelioma—an update on treatment. Cancer Treat Rev 2012;38:605–612.)| false
• Search Google Scholar
• Export Citation

Chekol SS, Sun CC. Malignant mesothelioma of the tunica vaginalis testis: diagnostic studies and differential diagnosis. Arch Pathol Lab Med 2012;136:113–117.

• PubMed
Chekol SS, Sun CC. Malignant mesothelioma of the tunica vaginalis testis: diagnostic studies and differential diagnosis. Arch Pathol Lab Med 2012;136:113–117.)| false
• Search Google Scholar
• Export Citation

Henley SJ, Peipins LA, Rim SH, et al. Geographic co-occurrence of mesothelioma and ovarian cancer incidence. J Womens Health (Larchmt) 2020;29:111–118.

• PubMed
Henley SJ, Peipins LA, Rim SH, Geographic co-occurrence of mesothelioma and ovarian cancer incidence. J Womens Health (Larchmt) 2020;29:111–118.)| false
• Search Google Scholar
• Export Citation

Ullah A, Waheed A, Khan J, et al. Incidence, survival analysis and future perspective of primary peritoneal mesothelioma (PPM): a population-based study from SEER database. Cancers (Basel) 2022;14:942.

• PubMed
Ullah A, Waheed A, Khan J, Incidence, survival analysis and future perspective of primary peritoneal mesothelioma (PPM): a population-based study from SEER database. Cancers (Basel) 2022;14:942.)| false
• Search Google Scholar
• Export Citation

Kusamura S, Baratti D, De Simone M, et al. Diagnostic and therapeutic pathway in diffuse malignant peritoneal mesothelioma. Cancers (Basel) 2023;15:662.

• PubMed
Kusamura S, Baratti D, De Simone M, Diagnostic and therapeutic pathway in diffuse malignant peritoneal mesothelioma. Cancers (Basel) 2023;15:662.)| false
• Search Google Scholar
• Export Citation

Bijelic L, Darcy K, Stodghill J, et al. Predictors and outcomes of surgery in peritoneal mesothelioma: an analysis of 2000 patients from the National Cancer Database. Ann Surg Oncol 2020;27:2974–2982.

• PubMed
Bijelic L, Darcy K, Stodghill J, Predictors and outcomes of surgery in peritoneal mesothelioma: an analysis of 2000 patients from the National Cancer Database. Ann Surg Oncol 2020;27:2974–2982.)| false
• Search Google Scholar
• Export Citation

Acs M, Gerken M, Gajic I, et al. Ten-year single-center experience with treatment of primary diffuse malignant peritoneal mesothelioma (DMPM) by cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Langenbecks Arch Surg 2022;407:3057–3067.

• PubMed
Acs M, Gerken M, Gajic I, Ten-year single-center experience with treatment of primary diffuse malignant peritoneal mesothelioma (DMPM) by cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Langenbecks Arch Surg 2022;407:3057–3067.)| false
• Search Google Scholar
• Export Citation

Chapel DB, Schulte JJ, Absenger G, et al. Malignant peritoneal mesothelioma: prognostic significance of clinical and pathologic parameters and validation of a nuclear-grading system in a multi-institutional series of 225 cases. Mod Pathol 2021;34:380–395.

• PubMed
Chapel DB, Schulte JJ, Absenger G, Malignant peritoneal mesothelioma: prognostic significance of clinical and pathologic parameters and validation of a nuclear-grading system in a multi-institutional series of 225 cases. Mod Pathol 2021;34:380–395.)| false
• Search Google Scholar
• Export Citation

Helm JH, Miura JT, Glenn JA, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis. Ann Surg Oncol 2015;22:1686–1693.

• PubMed
Helm JH, Miura JT, Glenn JA, Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis. Ann Surg Oncol 2015;22:1686–1693.)| false
• Search Google Scholar
• Export Citation

Husain AN, Colby TV, Ordóñez NG, et al. Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 2018;142:89–108.

• PubMed
Husain AN, Colby TV, Ordóñez NG, Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 2018;142:89–108.)| false
• Search Google Scholar
• Export Citation

Galateau-Salle F, Churg A, Roggli V, et al. The 2015 World Health Organization Classification of Tumors of the Pleura: advances since the 2004 classification. J Thorac Oncol 2016;11:142–154.

• PubMed
Galateau-Salle F, Churg A, Roggli V, The 2015 World Health Organization Classification of Tumors of the Pleura: advances since the 2004 classification. J Thorac Oncol 2016;11:142–154.)| false
• Search Google Scholar
• Export Citation

Henderson DW, Reid G, Kao SC, et al. Challenges and controversies in the diagnosis of malignant mesothelioma: part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1 and microRNA. J Clin Pathol 2013;66:854–861.

• PubMed
Henderson DW, Reid G, Kao SC, Challenges and controversies in the diagnosis of malignant mesothelioma: part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1 and microRNA. J Clin Pathol 2013;66:854–861.)| false
• Search Google Scholar
• Export Citation

Carbone M, Adusumilli PS, Alexander HR Jr, et al. Mesothelioma: scientific clues for prevention, diagnosis, and therapy. CA Cancer J Clin 2019;69:402–429.

• PubMed
Carbone M, Adusumilli PS, Alexander HR Jr, Mesothelioma: scientific clues for prevention, diagnosis, and therapy. CA Cancer J Clin 2019;69:402–429.)| false
• Search Google Scholar
• Export Citation

Kusamura S, Kepenekian V, Villeneuve L, et al. Peritoneal mesothelioma: PSOGI/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Eur J Surg Oncol 2021;47:36–59.

• PubMed
Kusamura S, Kepenekian V, Villeneuve L, Peritoneal mesothelioma: PSOGI/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Eur J Surg Oncol 2021;47:36–59.)| false
• Search Google Scholar
• Export Citation

Boffetta P. Epidemiology of peritoneal mesothelioma: a review. Ann Oncol 2007;18:985–990.

• PubMed
Boffetta P. Epidemiology of peritoneal mesothelioma: a review. Ann Oncol 2007;18:985–990.)| false
• Search Google Scholar
• Export Citation

Consonni D, Calvi C, De Matteis S, et al. Peritoneal mesothelioma and asbestos exposure: a population-based case-control study in Lombardy, Italy. Occup Environ Med 2019;76:545–553.

• PubMed
Consonni D, Calvi C, De Matteis S, Peritoneal mesothelioma and asbestos exposure: a population-based case-control study in Lombardy, Italy. Occup Environ Med 2019;76:545–553.)| false
• Search Google Scholar
• Export Citation

Kim J, Bhagwandin S, Labow DM. Malignant peritoneal mesothelioma: a review. Ann Transl Med 2017;5:236.

• PubMed
Kim J, Bhagwandin S, Labow DM. Malignant peritoneal mesothelioma: a review. Ann Transl Med 2017;5:236.)| false
• Search Google Scholar
• Export Citation

Alpert N, van Gerwen M, Taioli E. Epidemiology of mesothelioma in the 21st century in Europe and the United States, 40 years after restricted/banned asbestos use. Transl Lung Cancer Res 2020;9(Suppl 1):S28–38.

• PubMed
Alpert N, van Gerwen M, Taioli E. Epidemiology of mesothelioma in the 21st century in Europe and the United States, 40 years after restricted/banned asbestos use. Transl Lung Cancer Res 2020;9(Suppl 1):S28–38.)| false
• Search Google Scholar
• Export Citation

Delgermaa V, Takahashi K, Park EK, et al. Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008. Bull World Health Organ 2011;89:716–724C.

• PubMed
Delgermaa V, Takahashi K, Park EK, Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008. Bull World Health Organ 2011;89:716–724C.)| false
• Search Google Scholar
• Export Citation

Park EK, Takahashi K, Hoshuyama T, et al. Global magnitude of reported and unreported mesothelioma. Environ Health Perspect 2011;119:514–518.

• PubMed
Park EK, Takahashi K, Hoshuyama T, Global magnitude of reported and unreported mesothelioma. Environ Health Perspect 2011;119:514–518.)| false
• Search Google Scholar
• Export Citation

Bang KM, Mazurek JM, Storey E, et al. Malignant mesothelioma mortality—United States, 1999–2005. MMWR Morb Mortal Wkly Rep 2009;58:393–396.

• PubMed
Bang KM, Mazurek JM, Storey E, Malignant mesothelioma mortality—United States, 1999–2005. MMWR Morb Mortal Wkly Rep 2009;58:393–396.)| false
• Search Google Scholar
• Export Citation

Dagogo-Jack I, Madison RW, Lennerz JK, et al. Molecular characterization of mesothelioma: impact of histologic type and site of origin on molecular landscape. JCO Precis Oncol 2022;6:e2100422.

• PubMed
Dagogo-Jack I, Madison RW, Lennerz JK, Molecular characterization of mesothelioma: impact of histologic type and site of origin on molecular landscape. JCO Precis Oncol 2022;6:e2100422.)| false
• Search Google Scholar
• Export Citation

Borczuk AC, Pei J, Taub RN, et al. Genome-wide analysis of abdominal and pleural malignant mesothelioma with DNA arrays reveals both common and distinct regions of copy number alteration. Cancer Biol Ther 2016;17:328–335.

• PubMed
Borczuk AC, Pei J, Taub RN, Genome-wide analysis of abdominal and pleural malignant mesothelioma with DNA arrays reveals both common and distinct regions of copy number alteration. Cancer Biol Ther 2016;17:328–335.)| false
• Search Google Scholar
• Export Citation

Alakus H, Yost SE, Woo B, et al. BAP1 mutation is a frequent somatic event in peritoneal malignant mesothelioma. J Transl Med 2015;13:122.

• PubMed
Alakus H, Yost SE, Woo B, BAP1 mutation is a frequent somatic event in peritoneal malignant mesothelioma. J Transl Med 2015;13:122.)| false
• Search Google Scholar
• Export Citation

Hung YP, Dong F, Watkins JC, et al. Identification of ALK rearrangements in malignant peritoneal mesothelioma. JAMA Oncol 2018;4:235–238.

• PubMed
Hung YP, Dong F, Watkins JC, Identification of ALK rearrangements in malignant peritoneal mesothelioma. JAMA Oncol 2018;4:235–238.)| false
• Search Google Scholar
• Export Citation

Hung YP, Dong F, Torre M, et al. Molecular characterization of diffuse malignant peritoneal mesothelioma. Mod Pathol 2020;33:2269–2279.

• PubMed
Hung YP, Dong F, Torre M, Molecular characterization of diffuse malignant peritoneal mesothelioma. Mod Pathol 2020;33:2269–2279.)| false
• Search Google Scholar
• Export Citation

Leblay N, Leprêtre F, Le Stang N, et al. BAP1 is altered by copy number loss, mutation, and/or loss of protein expression in more than 70% of malignant peritoneal mesotheliomas. J Thorac Oncol 2017;12:724–733.

• PubMed
Leblay N, Leprêtre F, Le Stang N, BAP1 is altered by copy number loss, mutation, and/or loss of protein expression in more than 70% of malignant peritoneal mesotheliomas. J Thorac Oncol 2017;12:724–733.)| false
• Search Google Scholar
• Export Citation

Desmeules P, Joubert P, Zhang L, et al. A subset of malignant mesotheliomas in young adults are associated with recurrent EWSR1/FUS-ATF1 fusions. Am J Surg Pathol 2017;41:980–988.

• PubMed
Desmeules P, Joubert P, Zhang L, A subset of malignant mesotheliomas in young adults are associated with recurrent EWSR1/FUS-ATF1 fusions. Am J Surg Pathol 2017;41:980–988.)| false
• Search Google Scholar
• Export Citation

Dermawan JK, Torrence D, Lee CH, et al. EWSR1::YY1 fusion positive peritoneal epithelioid mesothelioma harbors mesothelioma epigenetic signature: Report of 3 cases in support of an emerging entity. Genes Chromosomes Cancer 2022;61:592–602.

• PubMed
Dermawan JK, Torrence D, Lee CH, EWSR1::YY1 fusion positive peritoneal epithelioid mesothelioma harbors mesothelioma epigenetic signature: Report of 3 cases in support of an emerging entity. Genes Chromosomes Cancer 2022;61:592–602.)| false
• Search Google Scholar
• Export Citation

Gerthofer V, Scheiter A, Lüke F, et al. STRN-ALK fusion in a case of malignant peritoneal mesothelioma: mixed response to crizotinib, mode of resistance, and brigatinib sequential therapy. JCO Precis Oncol 2021;5:PO.21.00184.

• PubMed
Gerthofer V, Scheiter A, Lüke F, STRN-ALK fusion in a case of malignant peritoneal mesothelioma: mixed response to crizotinib, mode of resistance, and brigatinib sequential therapy. JCO Precis Oncol 2021;5:PO.21.00184.)| false
• Search Google Scholar
• Export Citation

García-Fadrique A, Mehta A, Mohamed F, et al. Clinical presentation, diagnosis, classification and management of peritoneal mesothelioma: a review. J Gastrointest Oncol 2017;8:915–924.

• PubMed
García-Fadrique A, Mehta A, Mohamed F, Clinical presentation, diagnosis, classification and management of peritoneal mesothelioma: a review. J Gastrointest Oncol 2017;8:915–924.)| false
• Search Google Scholar
• Export Citation

Sauter JL, Dacic S, Galateau-Salle F, et al. The 2021 WHO Classification of Tumors of the Pleura: advances since the 2015 classification. J Thorac Oncol 2022;17:608–622.

• PubMed
Sauter JL, Dacic S, Galateau-Salle F, The 2021 WHO Classification of Tumors of the Pleura: advances since the 2015 classification. J Thorac Oncol 2022;17:608–622.)| false
• Search Google Scholar
• Export Citation

Hiltbrunner S, Fleischmann Z, Sokol ES, et al. Genomic landscape of pleural and peritoneal mesothelioma tumours. Br J Cancer 2022;127:1997–2005.

• PubMed
Hiltbrunner S, Fleischmann Z, Sokol ES, Genomic landscape of pleural and peritoneal mesothelioma tumours. Br J Cancer 2022;127:1997–2005.)| false
• Search Google Scholar
• Export Citation

Carlson B, Harmath C, Turaga K, et al. The role of imaging in diagnosis and management of malignant peritoneal mesothelioma: a systematic review. Abdom Radiol (NY) 2022;47:1725–1740.

• PubMed
Carlson B, Harmath C, Turaga K, The role of imaging in diagnosis and management of malignant peritoneal mesothelioma: a systematic review. Abdom Radiol (NY) 2022;47:1725–1740.)| false
• Search Google Scholar
• Export Citation

Yan TD, Haveric N, Carmignani CP, et al. Abdominal computed tomography scans in the selection of patients with malignant peritoneal mesothelioma for comprehensive treatment with cytoreductive surgery and perioperative intraperitoneal chemotherapy. Cancer 2005;103:839–849.

• PubMed
Yan TD, Haveric N, Carmignani CP, Abdominal computed tomography scans in the selection of patients with malignant peritoneal mesothelioma for comprehensive treatment with cytoreductive surgery and perioperative intraperitoneal chemotherapy. Cancer 2005;103:839–849.)| false
• Search Google Scholar
• Export Citation

Pickhardt PJ, Perez AA, Elmohr MM, et al. CT imaging review of uncommon peritoneal-based neoplasms: beyond carcinomatosis. Br J Radiol 2021;94:20201288.

• PubMed
Pickhardt PJ, Perez AA, Elmohr MM, CT imaging review of uncommon peritoneal-based neoplasms: beyond carcinomatosis. Br J Radiol 2021;94:20201288.)| false
• Search Google Scholar
• Export Citation

Shrestha R, Nabavi N, Volik S, et al. Well-differentiated papillary mesothelioma of the peritoneum is genetically distinct from malignant mesothelioma. Cancers (Basel) 2020;12:1568.

• PubMed
Shrestha R, Nabavi N, Volik S, Well-differentiated papillary mesothelioma of the peritoneum is genetically distinct from malignant mesothelioma. Cancers (Basel) 2020;12:1568.)| false
• Search Google Scholar
• Export Citation

Churg A, Allen T, Borczuk AC, et al. Well-differentiated papillary mesothelioma with invasive foci. Am J Surg Pathol 2014;38:990–998.

• PubMed
Churg A, Allen T, Borczuk AC, Well-differentiated papillary mesothelioma with invasive foci. Am J Surg Pathol 2014;38:990–998.)| false
• Search Google Scholar
• Export Citation

Malpica A, Sant’Ambrogio S, Deavers MT, et al. Well-differentiated papillary mesothelioma of the female peritoneum: a clinicopathologic study of 26 cases. Am J Surg Pathol 2012;36:117–127.

• PubMed
Malpica A, Sant’Ambrogio S, Deavers MT, Well-differentiated papillary mesothelioma of the female peritoneum: a clinicopathologic study of 26 cases. Am J Surg Pathol 2012;36:117–127.)| false
• Search Google Scholar
• Export Citation

Noiret B, Renaud F, Piessen G, et al. Multicystic peritoneal mesothelioma: a systematic review of the literature. Pleura Peritoneum 2019;4:20190024.

• PubMed
Noiret B, Renaud F, Piessen G, Multicystic peritoneal mesothelioma: a systematic review of the literature. Pleura Peritoneum 2019;4:20190024.)| false
• Search Google Scholar
• Export Citation

Baratti D, Vaira M, Kusamura S, et al. Multicystic peritoneal mesothelioma: outcomes and patho-biological features in a multi-institutional series treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Eur J Surg Oncol 2010;36:1047–1053.

• PubMed
Baratti D, Vaira M, Kusamura S, Multicystic peritoneal mesothelioma: outcomes and patho-biological features in a multi-institutional series treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Eur J Surg Oncol 2010;36:1047–1053.)| false
• Search Google Scholar
• Export Citation

Baratti D, Kusamura S, Nonaka D, et al. Multicystic and well- differentiated papillary peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intra-peritoneal chemotherapy (HIPEC). Ann Surg Oncol 2007;14:2790–2797.

• PubMed
Baratti D, Kusamura S, Nonaka D, Multicystic and well- differentiated papillary peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intra-peritoneal chemotherapy (HIPEC). Ann Surg Oncol 2007;14:2790–2797.)| false
• Search Google Scholar
• Export Citation

Chapel DB, Schulte JJ, Husain AN, et al. Application of immunohistochemistry in diagnosis and management of malignant mesothelioma. Transl Lung Cancer Res 2020;9(Suppl 1):S3–27.

• PubMed
Chapel DB, Schulte JJ, Husain AN, Application of immunohistochemistry in diagnosis and management of malignant mesothelioma. Transl Lung Cancer Res 2020;9(Suppl 1):S3–27.)| false
• Search Google Scholar
• Export Citation

Allen TC, Cagle PT, Churg AM, et al. Localized malignant mesothelioma. Am J Surg Pathol 2005;29:866–873.

• PubMed
Allen TC, Cagle PT, Churg AM, Localized malignant mesothelioma. Am J Surg Pathol 2005;29:866–873.)| false
• Search Google Scholar
• Export Citation

Marchevsky AM, Khoor A, Walts AE, et al. Localized malignant mesothelioma, an unusual and poorly characterized neoplasm of serosal origin: best current evidence from the literature and the International Mesothelioma Panel. Mod Pathol 2020;33:281–296.

• PubMed
Marchevsky AM, Khoor A, Walts AE, Localized malignant mesothelioma, an unusual and poorly characterized neoplasm of serosal origin: best current evidence from the literature and the International Mesothelioma Panel. Mod Pathol 2020;33:281–296.)| false
• Search Google Scholar
• Export Citation

Jeppesen TD, Højsgaard A, Kjær D, et al. Localized malignant mesothelioma in the stomach and mediastinum. Interact Cardiovasc Thorac Surg 2022;34:485–487.

• PubMed
Jeppesen TD, Højsgaard A, Kjær D, Localized malignant mesothelioma in the stomach and mediastinum. Interact Cardiovasc Thorac Surg 2022;34:485–487.)| false
• Search Google Scholar
• Export Citation

Liu S, Staats P, Lee M, et al. Diffuse mesothelioma of the peritoneum: correlation between histological and clinical parameters and survival in 73 patients. Pathology 2014;46:604–609.

• PubMed
Liu S, Staats P, Lee M, Diffuse mesothelioma of the peritoneum: correlation between histological and clinical parameters and survival in 73 patients. Pathology 2014;46:604–609.)| false
• Search Google Scholar
• Export Citation

Rizzuto I, Power T, Oehler MK. Diffuse peritoneal malignant mesothelioma presenting with abnormal uterine bleeding: case report. Case Rep Oncol 2022;15:251–256.

• PubMed
Rizzuto I, Power T, Oehler MK. Diffuse peritoneal malignant mesothelioma presenting with abnormal uterine bleeding: case report. Case Rep Oncol 2022;15:251–256.)| false
• Search Google Scholar
• Export Citation

Lin LC, Kuan WY, Shiu BH, et al. Primary malignant peritoneal mesothelioma mimicking tuberculous peritonitis: a case report. World J Clin Cases 2022;10:3156–3163.

• PubMed
Lin LC, Kuan WY, Shiu BH, Primary malignant peritoneal mesothelioma mimicking tuberculous peritonitis: a case report. World J Clin Cases 2022;10:3156–3163.)| false
• Search Google Scholar
• Export Citation

WHO Classification of Tumours Editorial Board. WHO Classification of Tumours: Thoracic Tumours. 5th ed. International Agency for Research on Cancer; 2021.

• PubMed
WHO Classification of Tumours Editorial Board. WHO Classification of Tumours: Thoracic Tumours. 5th ed. International Agency for Research on Cancer; 2021.)| false
• Search Google Scholar
• Export Citation

Schneider F, Roden AC, Dacic S, et al. Protocol for the examination of specimens from patients with malignant pleural mesothelioma: version 4.1.0.0. Accessed February 1, 2023. Available at: https://documents.cap.org/protocols/PleuraPericard_4.1.0.0.REL_CAPCP.pdf

• PubMed
Schneider F, Roden AC, Dacic S, Protocol for the examination of specimens from patients with malignant pleural mesothelioma: version 4.1.0.0. Accessed February 1, 2023. Available at: https://documents.cap.org/protocols/PleuraPericard_4.1.0.0.REL_CAPCP.pdf)| false
• Search Google Scholar
• Export Citation

Malpica A, Euscher ED, Marques-Piubelli ML, et al. Malignant mesothelioma of the peritoneum in women: a clinicopathologic study of 164 cases. Am J Surg Pathol 2021;45:45–58.

• PubMed
Malpica A, Euscher ED, Marques-Piubelli ML, Malignant mesothelioma of the peritoneum in women: a clinicopathologic study of 164 cases. Am J Surg Pathol 2021;45:45–58.)| false
• Search Google Scholar
• Export Citation

Kindler HL, Ismaila N, Armato SG III, et al. Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2018;36:1343–1373.

• PubMed
Kindler HL, Ismaila N, Armato SG III, Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2018;36:1343–1373.)| false
• Search Google Scholar
• Export Citation

Chapel DB, Churg A, Santoni-Rugiu E, et al. Molecular pathways and diagnosis in malignant mesothelioma: a review of the 14th International Conference of the International Mesothelioma Interest Group. Lung Cancer 2019;127:69–75.

• PubMed
Chapel DB, Churg A, Santoni-Rugiu E, Molecular pathways and diagnosis in malignant mesothelioma: a review of the 14th International Conference of the International Mesothelioma Interest Group. Lung Cancer 2019;127:69–75.)| false
• Search Google Scholar
• Export Citation

Henderson DW, Reid G, Kao SC, et al. Challenges and controversies in the diagnosis of mesothelioma: part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers. J Clin Pathol 2013;66:847–853.

• PubMed
Henderson DW, Reid G, Kao SC, Challenges and controversies in the diagnosis of mesothelioma: part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers. J Clin Pathol 2013;66:847–853.)| false
• Search Google Scholar
• Export Citation

Husain AN, Colby T, Ordonez N, et al. Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 2013;137:647–667.

• PubMed
Husain AN, Colby T, Ordonez N, Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 2013;137:647–667.)| false
• Search Google Scholar
• Export Citation

Husain AN, Colby TV, Ordóñez NG, et al. Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 2009;133:1317–1331.

• PubMed
Husain AN, Colby TV, Ordóñez NG, Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 2009;133:1317–1331.)| false
• Search Google Scholar
• Export Citation

Chapel DB, Husain AN, Krausz T, et al. PAX8 expression in a subset of malignant peritoneal mesotheliomas and benign mesothelium has diagnostic implications in the differential diagnosis of ovarian serous carcinoma. Am J Surg Pathol 2017;41:1675–1682.

• PubMed
Chapel DB, Husain AN, Krausz T, PAX8 expression in a subset of malignant peritoneal mesotheliomas and benign mesothelium has diagnostic implications in the differential diagnosis of ovarian serous carcinoma. Am J Surg Pathol 2017;41:1675–1682.)| false
• Search Google Scholar
• Export Citation

Offin M, Yang SR, Egger J, et al. Molecular characterization of peritoneal mesotheliomas. J Thorac Oncol 2022;17:455–460.

• PubMed
Offin M, Yang SR, Egger J, Molecular characterization of peritoneal mesotheliomas. J Thorac Oncol 2022;17:455–460.)| false
• Search Google Scholar
• Export Citation

Churg A, Naso JR. The separation of benign and malignant mesothelial proliferations: new markers and how to use them. Am J Surg Pathol 2020;44:e100–112.

• PubMed
Churg A, Naso JR. The separation of benign and malignant mesothelial proliferations: new markers and how to use them. Am J Surg Pathol 2020;44:e100–112.)| false
• Search Google Scholar
• Export Citation

Singhi AD, Krasinskas AM, Choudry HA, et al. The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma. Mod Pathol 2016;29:14–24.

• PubMed
Singhi AD, Krasinskas AM, Choudry HA, The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma. Mod Pathol 2016;29:14–24.)| false
• Search Google Scholar
• Export Citation

Tandon RT, Jimenez-Cortez Y, Taub R, et al. Immunohistochemistry in peritoneal mesothelioma: a single-center experience of 244 cases. Arch Pathol Lab Med 2018;142:236–242.

• PubMed
Tandon RT, Jimenez-Cortez Y, Taub R, Immunohistochemistry in peritoneal mesothelioma: a single-center experience of 244 cases. Arch Pathol Lab Med 2018;142:236–242.)| false
• Search Google Scholar
• Export Citation

Kawai T, Tominaga S, Hiroi S, et al. Peritoneal malignant mesothelioma (PMM), and primary peritoneal serous carcinoma (PPSC) and reactive mesothelial hyperplasia (RMH) of the peritoneum. Immunohistochemical and fluorescence in situ hybridisation (FISH) analyses. J Clin Pathol 2016;69:706–712.

• PubMed
Kawai T, Tominaga S, Hiroi S, Peritoneal malignant mesothelioma (PMM), and primary peritoneal serous carcinoma (PPSC) and reactive mesothelial hyperplasia (RMH) of the peritoneum. Immunohistochemical and fluorescence in situ hybridisation (FISH) analyses. J Clin Pathol 2016;69:706–712.)| false
• Search Google Scholar
• Export Citation

Andrici J, Jung J, Sheen A, et al. Loss of BAP1 expression is very rare in peritoneal and gynecologic serous adenocarcinomas and can be useful in the differential diagnosis with abdominal mesothelioma. Hum Pathol 2016;51:9–15.

• PubMed
Andrici J, Jung J, Sheen A, Loss of BAP1 expression is very rare in peritoneal and gynecologic serous adenocarcinomas and can be useful in the differential diagnosis with abdominal mesothelioma. Hum Pathol 2016;51:9–15.)| false
• Search Google Scholar
• Export Citation

Schulte JJ, Husain AN. Update on the pathologic diagnosis of malignant mesothelioma. Transl Lung Cancer Res 2020;9:917–923.

• PubMed
Schulte JJ, Husain AN. Update on the pathologic diagnosis of malignant mesothelioma. Transl Lung Cancer Res 2020;9:917–923.)| false
• Search Google Scholar
• Export Citation

Krasinskas AM, Bartlett DL, Cieply K, et al. CDKN2A and MTAP deletions in peritoneal mesotheliomas are correlated with loss of p16 protein expression and poor survival. Mod Pathol 2010;23:531–538.

• PubMed
Krasinskas AM, Bartlett DL, Cieply K, CDKN2A and MTAP deletions in peritoneal mesotheliomas are correlated with loss of p16 protein expression and poor survival. Mod Pathol 2010;23:531–538.)| false
• Search Google Scholar
• Export Citation

Schuitevoerder D, Izquierdo FJ, Plana A, et al. The Chicago Consensus on peritoneal surface malignancies: management of peritoneal mesothelioma. Cancer 2020;126:2547–2552.

• PubMed
Schuitevoerder D, Izquierdo FJ, Plana A, The Chicago Consensus on peritoneal surface malignancies: management of peritoneal mesothelioma. Cancer 2020;126:2547–2552.)| false
• Search Google Scholar
• Export Citation

Feldman AL, Libutti SK, Pingpank JF, et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol 2003;21:4560–4567.

• PubMed
Feldman AL, Libutti SK, Pingpank JF, Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol 2003;21:4560–4567.)| false
• Search Google Scholar
• Export Citation

Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol 2009;27:6237–6242.

• PubMed
Yan TD, Deraco M, Baratti D, Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol 2009;27:6237–6242.)| false
• Search Google Scholar
• Export Citation

Baratti D, Kusamura S, Cabras AD, et al. Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC). Eur J Cancer 2013;49:3140–3148.

• PubMed
Baratti D, Kusamura S, Cabras AD, Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC). Eur J Cancer 2013;49:3140–3148.)| false
• Search Google Scholar
• Export Citation

Votanopoulos KI, Sugarbaker P, Deraco M, et al. Is cytoreductive surgery with hyperthermic intraperitoneal chemotherapy justified for biphasic variants of peritoneal mesothelioma? Outcomes from the Peritoneal Surface Oncology Group International Registry. Ann Surg Oncol 2018;25:667–673.

• PubMed
Votanopoulos KI, Sugarbaker P, Deraco M, Is cytoreductive surgery with hyperthermic intraperitoneal chemotherapy justified for biphasic variants of peritoneal mesothelioma? Outcomes from the Peritoneal Surface Oncology Group International Registry. Ann Surg Oncol 2018;25:667–673.)| false
• Search Google Scholar
• Export Citation

Kaufman AJ, Flores RM. Surgical treatment of malignant pleural mesothelioma. Curr Treat Options Oncol 2011;12:201–216.

• PubMed
Kaufman AJ, Flores RM. Surgical treatment of malignant pleural mesothelioma. Curr Treat Options Oncol 2011;12:201–216.)| false
• Search Google Scholar
• Export Citation

Sugarbaker DJ, Flores RM, Jaklitsch MT, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999;117:54–63; discussion 63–65.

• PubMed
Sugarbaker DJ, Flores RM, Jaklitsch MT, Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999;117:54–63; discussion 63–65.)| false
• Search Google Scholar
• Export Citation

Yan TD, Deraco M, Elias D, et al. A novel tumor-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database. Cancer 2011;117:1855–1863.

• PubMed
Yan TD, Deraco M, Elias D, A novel tumor-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database. Cancer 2011;117:1855–1863.)| false
• Search Google Scholar
• Export Citation

Kusamura S, Baratti D, Younan R, et al. Impact of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on systemic toxicity. Ann Surg Oncol 2007;14:2550–2558.

• PubMed
Kusamura S, Baratti D, Younan R, Impact of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on systemic toxicity. Ann Surg Oncol 2007;14:2550–2558.)| false
• Search Google Scholar
• Export Citation

Shetty SJ, Bathla L, Govindarajan V, et al. Comparison of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with mitomycin or carboplatin for diffuse malignant peritoneal mesothelioma. Am Surg 2014;80:348–352.

• PubMed
Shetty SJ, Bathla L, Govindarajan V, Comparison of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with mitomycin or carboplatin for diffuse malignant peritoneal mesothelioma. Am Surg 2014;80:348–352.)| false
• Search Google Scholar
• Export Citation

Kepenekian V, Elias D, Passot G, et al. Diffuse malignant peritoneal mesothelioma: evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE Database: multi-institutional retrospective study. Eur J Cancer 2016;65:69–79.

• PubMed
Kepenekian V, Elias D, Passot G, Diffuse malignant peritoneal mesothelioma: evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE Database: multi-institutional retrospective study. Eur J Cancer 2016;65:69–79.)| false
• Search Google Scholar
• Export Citation

Raghav K, Liu S, Overman MJ, et al. Efficacy, safety, and biomarker analysis of combined PD-L1 (atezolizumab) and VEGF (bevacizumab) blockade in advanced malignant peritoneal mesothelioma. Cancer Discov 2021;11:2738–2747.

• PubMed
Raghav K, Liu S, Overman MJ, Efficacy, safety, and biomarker analysis of combined PD-L1 (atezolizumab) and VEGF (bevacizumab) blockade in advanced malignant peritoneal mesothelioma. Cancer Discov 2021;11:2738–2747.)| false
• Search Google Scholar
• Export Citation

Jänne PA, Wozniak AJ, Belani CP, et al. Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program. Clin Lung Cancer 2005;7:40–46.

• PubMed
Jänne PA, Wozniak AJ, Belani CP, Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program. Clin Lung Cancer 2005;7:40–46.)| false
• Search Google Scholar
• Export Citation

Kitadai R, Shimoi T, Sudo K, et al. Efficacy of second-line treatment and prognostic factors in patients with advanced malignant peritoneal mesothelioma: a retrospective study. BMC Cancer 2021;21:294.

• PubMed
Kitadai R, Shimoi T, Sudo K, Efficacy of second-line treatment and prognostic factors in patients with advanced malignant peritoneal mesothelioma: a retrospective study. BMC Cancer 2021;21:294.)| false
• Search Google Scholar
• Export Citation

Fennell DA, Ewings S, Ottensmeier C, et al. Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial. Lancet Oncol 2021;22:1530–1540.

• PubMed
Fennell DA, Ewings S, Ottensmeier C, Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial. Lancet Oncol 2021;22:1530–1540.)| false
• Search Google Scholar
• Export Citation

Nagata Y, Sawada R, Takashima A, et al. Efficacy and safety of pemetrexed plus cisplatin as first-line chemotherapy in advanced malignant peritoneal mesothelioma. Jpn J Clin Oncol 2019;49:1004–1008.

• PubMed
Nagata Y, Sawada R, Takashima A, Efficacy and safety of pemetrexed plus cisplatin as first-line chemotherapy in advanced malignant peritoneal mesothelioma. Jpn J Clin Oncol 2019;49:1004–1008.)| false
• Search Google Scholar
• Export Citation

Kim JS, Lim SY, Hwang J, et al. A case report of primary pericardial malignant mesothelioma treated with pemetrexed and cisplatin. J Korean Med Sci 2017;32:1879–1884.

• PubMed
Kim JS, Lim SY, Hwang J, A case report of primary pericardial malignant mesothelioma treated with pemetrexed and cisplatin. J Korean Med Sci 2017;32:1879–1884.)| false
• Search Google Scholar
• Export Citation

Recabal P, Rosenzweig B, Bazzi WM, et al. Malignant mesothelioma of the tunica vaginalis testis: outcomes following surgical management beyond radical orchiectomy. Urology 2017;107:166–170.

• PubMed
Recabal P, Rosenzweig B, Bazzi WM, Malignant mesothelioma of the tunica vaginalis testis: outcomes following surgical management beyond radical orchiectomy. Urology 2017;107:166–170.)| false
• Search Google Scholar
• Export Citation

Santoro A, O’Brien ME, Stahel RA, et al. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program. J Thorac Oncol 2008;3:756–763.

• PubMed
Santoro A, O’Brien ME, Stahel RA, Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program. J Thorac Oncol 2008;3:756–763.)| false
• Search Google Scholar
• Export Citation

Jänne PA, Wozniak AJ, Belani CP, et al. Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program. J Thorac Oncol 2006;1:506–512.

• PubMed
Jänne PA, Wozniak AJ, Belani CP, Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program. J Thorac Oncol 2006;1:506–512.)| false
• Search Google Scholar
• Export Citation

Obasaju CK, Ye Z, Wozniak AJ, et al. Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: outcomes of an expanded access program. Lung Cancer 2007;55:187–194.

• PubMed
Obasaju CK, Ye Z, Wozniak AJ, Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: outcomes of an expanded access program. Lung Cancer 2007;55:187–194.)| false
• Search Google Scholar
• Export Citation

Fujimoto E, Kijima T, Kuribayashi K, et al. First-line chemotherapy with pemetrexed plus cisplatin for malignant peritoneal mesothelioma. Expert Rev Anticancer Ther 2017;17:865–872.

• PubMed
Fujimoto E, Kijima T, Kuribayashi K, First-line chemotherapy with pemetrexed plus cisplatin for malignant peritoneal mesothelioma. Expert Rev Anticancer Ther 2017;17:865–872.)| false
• Search Google Scholar
• Export Citation

Kim ST, Park JY, Lee J, et al. The efficacy of the frontline platinum-based combination chemotherapy in malignant peritoneal mesothelioma. Jpn J Clin Oncol 2010;40:1031–1036.

• PubMed
Kim ST, Park JY, Lee J, The efficacy of the frontline platinum-based combination chemotherapy in malignant peritoneal mesothelioma. Jpn J Clin Oncol 2010;40:1031–1036.)| false
• Search Google Scholar
• Export Citation

Tanida S, Kataoka H, Kubota E, et al. Combination chemotherapy with cisplatin and gemcitabine in malignant peritoneal mesothelioma. Int J Clin Oncol 2009;14:266–269.

• PubMed
Tanida S, Kataoka H, Kubota E, Combination chemotherapy with cisplatin and gemcitabine in malignant peritoneal mesothelioma. Int J Clin Oncol 2009;14:266–269.)| false
• Search Google Scholar
• Export Citation

Kobayashi S, Waragai T, Sano H, et al. Malignant peritoneal mesothelioma in a child: chemotherapy with gemcitabine and platinum was effective for the disease unresponsive to other treatments. Anticancer Drugs 2014;25:1102–1105.